<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lewis, Sally</style></author><author><style face="normal" font="default" size="100%">Telgenhoff, Dale</style></author><author><style face="normal" font="default" size="100%">Dubansky, Brooke</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular Characterization of Colorectal Cancers</style></title><secondary-title><style face="normal" font="default" size="100%">American Society for Clinical Laboratory Science</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1-6</style></pages><doi><style  face="normal" font="default" size="100%">10.29074/ascls.2022003208</style></doi><volume><style face="normal" font="default" size="100%">37</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">Characterization of the molecular mutations in colorectal cancers has made great progress since the initial report by Fearon and Vogelstein describing a series of histologic changes that correlate to a series of mutations. Since 1990, numerous mutational pathways have been associated with 1 or more actionable targets leading to more precise treatments in the development of colorectal cancers, including inherited and sporadic ones. The accumulation of mutations leads to the acquisition of cancer-promoting qualities such as increased cellular proliferation, immune evasion, and resistance to apoptosis. Mutations of tumor suppressor and protooncogenes such as KRAS and BRAF have an important role in the prognosis and therapeutic selection of treatment. Broadening the use of multigene next-generation sequencing panels in patients with colorectal cancer may allow earlier identification of more actionable targets in patients, providing more precise treatments.</style></abstract></record></records></xml>